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Understanding hypertension through genetic manipulation in number and randomly integrate into the mouse genome
mice. With the advances in mouse molecular genetics and phys- as a single unit. It is essential to recognize that both copy
iology during the last decade, the mouse has become the animal number and location in the genome may affect transgenemodel of choice for studying the genetic basis of many diseases.
expression. This is because transcriptional regulatory el-Terms such as “transgenic” and “knockout” have become part
ements (enhancers and/or repressors) located in genomicof a colloquial language used in most research laboratories
that are investigating human diseases. These terms refer to the DNA near the transgene integration site can have a pro-
two most commonly used methods for analyzing the function of found influence on transgene expression. Interestingly,
a gene in vivo: overexpression (transgenic mouse) and deletion some transgenes possess a series of regulatory elements(knockout mouse). Both methods have proved to be extremely
that form a “locus control region” that can insulate themuseful in establishing the importance of specific genes in genetic
disorders, such as hypertension. The choice of genes being from transcriptional regulators located at the site of in-
investigated in relationship to hypertension was governed by sertion. The expression of such genes is dependent on only
the knowledge of systems regulating vascular and renal physiol- the sequences they carry, and their expression becomes
ogy. Thus, it is not surprising that most of the focus was given
proportional to transgene copy number. The b-globin andto the renin-angiotensin system (RAS). Apart from the RAS,
human angiotensinogen (AGT) genes are examples [4, 5].other systems known to regulate vascular tone and/or electro-
lyte and fluid homeostasis have also been analyzed using trans- Because most transgenes are not immune from position
genic and knockout approaches. This review briefly summa- effects, it is generally necessary to establish several inde-
rizes some of the mouse models relevant to renal mechanisms pendent transgenic lines for every overexpressed geneof hypertension and then discusses the future of genetic manip-
to ensure that the phenotypic alterations caused by theirulation in mice for studying the genetics of hypertension.
expression are not due to position effects.
Deletion of a gene can be informative of its function
by assessing the perturbations caused by its absence.It is important to recognize the strengths and limita-
In practice, a comparison of the phenotypes betweentions of genetic manipulation in mice before analyzing
heterozygous (1/2) and homozygous (2/2) null micemouse models of hypertension. Gene function in vivo is
can help determine the significance of the gene. Althoughstudied most often by using two approaches: overexpres-
technically more laborious, gene targeting technologysion and deletion of a candidate gene. Overexpression
used to create “knockout” (KO) mice results in a muchstudies can help elucidate normal tissue- and cell-specific
more elegant manipulation of the genome [6]. Unlikeexpression patterns of a gene and can lead to physiologic
“regular” transgenic mice, this procedure allows for tar-changes in the mouse, both of which can be informative
geting of specific genetic loci in the mouse genome byabout the function of the gene product. This is achieved
by creating transgenic mice by pronuclear injection of relying on endogenous cell mechanisms that stimulate
naked DNA into fertilized eggs [1–3]. These DNA mole- recombination between homologous DNA sequences.
cules, which carry regulatory and coding sequences of Gene targeting is performed in cultures of embryonic
the gene, aggregate into concatamers of variable copy stem (ES) cells using targeting vectors consisting of mod-
ified gene sequences and a selectable marker, both
flanked by a region of DNA homologous to the targetedKey words: mouse models, animal models, genetics of disease, trans-
genic mouse, knockout mouse, hypertension, renin-angiotensin system. locus [7, 8]. Recombinant ES cells are identified and
injected into blastocysts, where they can contribute toReceived for publication April 19, 1999
the development of a chimera, in which the organ compo-and in revised form July 22, 1999
Accepted for publication August 24, 1999 sition is “marbled” by wild-type and mutant cells. In
chimeric mice, a variable population of the cells carryÓ 2000 by the International Society of Nephrology
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the gene modification, and therefore, a true heterozygous could not account for the hypertensive phenotype, be-
cause acute systemic ACE inhibition did not completelyKO mouse is not produced until germline transmission
is achieved. Mice homozygous for the deletion can then normalize their blood pressure. Data demonstrating the
expression of the hREN and hAGT transgenes in thebe generated by subsequent breeding of the heterozy-
gous (1/2) mice. brain lead us to hypothesize that activation of the brain
RAS may play a role in the blood pressure elevation inAlthough gene targeting technology is most often used
to generate a gene deletion (KO), its use is far more this model [21]. Indeed, intracerebroventricular adminis-
tration of the selective Ang II type 1 (AT-1) receptorversatile. As discussed later in this review, it can be used
to generate specific mutations in a gene or in regulating inhibitor losartan to hAGT/hREN mice caused a 30 mm
Hg decrease in pressure, suggesting that the activationspatial and temporal expression of a gene of interest.
Importantly, because the manipulation of the mouse ge- of AT-1 receptors in the central nervous system (CNS)
plays a role in development of hypertension in this modelnome is a controlled event, it is not essential to establish
independent mouse lines because all recombination [22]. Moreover, the increased CNS AT-1 receptor activ-
ity was associated with increased arginine vasopressinevents result in identical genetic modifications in the end.
(AVP) outflow from the CNS, but not an increase in
sympathetic nerve activity, a finding confirmed by the
TRANSGENIC AND KNOCKOUT
elevated levels of circulating AVP.
MOUSE MODELS OF THE
Expression of hAGT in the systemic model discussed
RENIN-ANGIOTENSIN SYSTEM
previously in this article was controlled by its own endog-
The renin-angiotensin system (RAS) is a multienzy- enous promoter, which targets hAGT mRNA to liver,
matic cascade in which AGT, the substrate, is processed kidney, brain, heart, and adipose tissue, and results in
in a two-step reaction by renin (REN) and angiotensin- high levels of hAGT protein in plasma [14]. To specifi-
converting enzyme (ACE), resulting in the production cally test the importance of the RAS in the kidney in
of the physiologically active octamer peptide angiotensin the regulation of blood pressure and renal physiology,
II (Ang II). Upon binding to its receptors, Ang II induces a new transgenic mouse line was developed expressing
a number of responses, including increased smooth mus- hAGT under control of the kidney androgen-inducible
cle tone, aldosterone biosynthesis, sodium reabsorption, (KAP) promoter [23]. Like the endogenous KAP gene,
and sensation of thirst, which can all lead to an increase these mice express the human transgene exclusively in
in blood volume and arterial pressure. Although the proximal tubule cells of the kidney, the site of endoge-
primary site of endocrine Ang II production is in plasma, nous mAGT production in kidney, but not at other extra-
all of the components of this system were found to be renal sites of AGT synthesis such as liver, heart, or brain.
expressed in several tissues, including kidney, suggesting Unlike the original hAGT transgenic model, KAP-hAGT
that tissue RAS may have a significant role in organ mice have measurable amounts of hAGT in urine, but
development and function. not plasma. Interestingly, double transgenic hREN/KAP-
hAGT mice are hypertensive, even though their plasma
Transgenic mice levels of Ang-II are normal. Moreover, these kidney-
The functions of the REN and AGT genes were first specific mice are more refractory than systemic hREN/
studied by overexpression of the rat and human genes. hAGT mice to the blood pressure-lowering effects of
Mice transgenic for rat AGT (rAGT) under the control losartan [24]. These results highlight the importance of a
of its endogenous promoter exhibit elevated AGT levels locally active RAS in the kidney in the regulation of
and develop high blood pressure [9]. Similar results were systemic blood pressure. Experiments are under way to
obtained from mice transgenic for both rAGT and rREN deduce further the mechanism(s) leading to the observed
under control of the partially inducible mouse metallo- phenotype in these mice.
thionein-1 promoter [10]. We and others have developed Although not included in this review restricted to
and characterized transgenic mice carrying either the mouse models, the reader is referred to the very impor-
human AGT (hAGT) and human renin (hREN) genes tant contributions made to this field by transgenic rat
[11–16]. Because of the established species-specific inter- models expressing the RAS [25, 26].
action between antiotensinogen and renin [17], the blood
Knockout micepressure of hAGT and hREN single transgenic mice does
not differ from wild-type controls. Only after crossing the In addition to overexpression, a number of RAS KO
two strains did the offspring develop severe hypertension mouse strains have been established. These models have
[18–20]. These double transgenic mice have increased been used to prove unequivocally that the RAS is central
plasma Ang II, and the kidneys develop the characteristic for the proper development of the kidney and that the
renal lesions exhibited in hypertension. Further analysis RAS contributes to physiological regulation of fluid ho-
meostasis. Before describing these models, it is importantindicated that increased levels of plasma Ang II alone
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to note that certain genetic differences exist between the blood pressure in male ACE1/2 mice was reported in
one study [34], but not another study from the sameRAS in humans and mice. Although both species contain
a single copy of the AGT, ACE and angiotensin type 2 group [36], or another group [35]. In addition to regular
ACE null mice, an oversight in construct design serendip-(AT-2) receptor genes, some species of wild mice and
some inbred strains of laboratory mice (including strain itously provided an opportunity to examine the differen-
tial roles of tissue and plasma ACE [37]. An unsuspected129, which is the most frequently used strain of ES cells
for gene targeting) carry two copies of the REN gene cryptic splice site in the ACE targeting vector resulted
in an ACE mRNA (termed ACE.2), which lacks the(Ren-1d and Ren-2d) [27, 28], and all mice apparently
have two subtypes of the AT-1 receptor gene (AT-1a coding sequence for a domain required for cell mem-
brane attachment. The resulting homozygous ACE.22/2and AT-1b).
Although the loss of a single AGT gene (mAGT1/2) mice have no tissue ACE activity but have plasma Ang I
conversion activity similar to heterozygous ACE1/2 mice,has only moderate effects on blood pressure, homozy-
gous mAGT 2/2 mice are severely hypotensive and ex- which are normotensive. However, the chronically hypo-
tensive phenotype of ACE.22/2 mice indicates thathibit severe renal abnormalities. Histologic evaluation
revealed atrophied medullary regions, papillary hypopla- plasma ACE activity is not sufficient to compensate for
the loss of a normal ACE gene. The importance of tissuesia, moderate to severe medial thickening of arterial
walls, dilated tubules, cystic spaces around glomeruli, ACE is also evident from the renal histology and physiol-
ogy of the ACE.22/2 mice, which qualitatively mimicsand multiple areas of interstitial fibrosis [29, 30]. These
renal abnormalities start to develop shortly after birth that of regular ACE null mice. However, the degree of
renal pathology does differ in ACE.22/2 mice, primarilyand cause a marked increase in mortality in the mAGT 2/2
pups. This phenotype in mAGT 2/2 mice can be rescued with respect to medullary and papillary development,
which in the majority of animals was indistinguishableby mating with mice transgenic for mAGT under metal-
lothionein-1 promoter control (MT-1mAgt) or with dou- from the control mice. Normal development of these
renal structures indicated that the urinary concentratingble transgenic hAGT/hREN mice, strongly indicating the
phenotype to be Ang-II dependent [31, 32]. Because defect observed in mAGT 2/2 and ACE2/2 strains is not
secondary to the lack of a normal renal papilla.MT-1mAgt/mAGT 2/2 mice produce AGT primarily in
plasma, these results suggest that the presence of Ang As mentioned previously in this article, the mouse
genome carries two genes encoding subtypes of the AT-1II in plasma is sufficient to rescue the defect in renal
development caused by the absence of AGT. We are receptor (on different chromosomes) and one for AT-2
receptor. Functional deletion of all three Ang II receptorcurrently investigating whether kidney-specific expres-
sion of the RAS can also rescue the renal defects ob- genes has been achieved, and an analysis of the mutant
mice revealed their roles in RAS signaling. AT-1a2/2served in mAGT 2/2 mice.
The mAGT 2/2 mice exhibited an increase in plasma mice have a phenotype intermediate between mAGT 2/2
and ACE2/2 mice [38–40]. They are moderately hypoten-creatinine and a decrease in glomerular filtration rate
on low-, normal-, and high-sodium diets compared with sive and have a milder degree of renal abnormalities
than mAGT 2/2 or ACE2/2 mice, indicating that AT-1atheir wild-type counterparts [33]. In contrast to wild-type
mice, however, glomerular filtration rate significantly in- is a primary receptor for Ang II signaling in kidney, a
finding supported by expression studies [41]. The notioncreased in mAGT 2/2 mice in response to increasing di-
etary sodium. These mice are also unable to concentrate that the AT-1a receptor is a main link in Ang II signaling
is further illustrated by the lack of blood pressure changetheir urine and exhibited hyposthenuria and polydipsia
[33]. Although hypotensive on normal (0.46%) salt, their during acute infusions of Ang II in AT-1a2/2 mice [40].
Detailed analysis of the effects of AT-1a receptor lossblood pressure decreased when put on low salt (0.02%)
and increased when placed on high (3.15%) salt. The in kidney indicated that the RAS is an essential compo-
nent in tubuloglomerular feedback (TGF) [42]. Thissalt-induced increase in blood pressure in mAGT 2/2 mice
was paralleled by a small but significant increase in urine feedback mechanism is virtually absent in AT-1a2/2 mice,
as kidney stop flow pressure remains unchanged follow-osmolality. Nevertheless, urine osmolality was lower in
mAGT 2/2 mice than in control mice under all dietary ing changes in the loop perfusion rate, indicating the
importance of the Ang II signaling through AT-1a recep-conditions tested.
The phenotype of ACE2/2 mice is almost identical to tor for maintenance of the TGF response. Increased
expression and activity of neuronal type nitric oxide syn-mAGT 2/2 [34, 35]. Mice lacking ACE exhibit marked
hypotension and reduced postnatal viability, indicating thase (nNOS) in AT-1a2/2 mice further illustrates the
importance of the RAS in this response [43].that it is the lack of Ang II, and not AGT(des-angioten-
sin), that is responsible for the shared phenotype. Het- AT-1b2/2 mice show no significant differences in blood
pressure and renal function compared with wild-typeerozygous ACE1/2 mice have normal kidney morphology
and renal function. A sexually dimorphic decrease in mice [44]. In addition, AT-1b2/2 mice, unlike AT-1a2/2
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mice, retain a normal pressor response to Ang II infu- OTHER TRANSGENIC AND KNOCKOUT
MODELS OF HYPERTENSIONsion. The development of AT-1a2/2/AT-1b2/2 double KO
mice allowed more insight into the function of AT-1b Nitric oxide synthase
receptor function, as these mice have a much more severe Nitric oxide is a potent vasodilator and has been pro-
phenotype than either AT-1a2/2 or AT-1b2/2 mice [45, 46]. posed to be the elusive endothelium-dependent relaxing
The comparison between single- and the double-receptor factor that mediates vasodilation in response to various
mutants confirmed that there is a level of redundancy stimuli [51, 52]. Mice lacking all three types of NOS
in signaling between these two receptors. In contrast to [neuronal NOS (nNOS), inducible NOS (iNOS), and
double KO mice, mice carrying an intact AT-1b receptor endothelial (eNOS)] have been generated and analyzed
gene (AT-1a2/2 mice) had less renal pathology and some- with respect to their effect on blood pressure. An analysis
what increased vascular tone and blood pressure (by 15 of nNOS expression in AT-1a2/2 mice showed that NO is
mm Hg), indicating partial restoration of Ang II signal- involved in normal physiologic regulation of renal blood
ing. Recent data suggest that the renal pathology caused flow and electrolyte homeostasis [43]. Somewhat surpris-
by the absence of AT-1 receptors may also be genetically ingly, mice lacking nNOS and iNOS showed no blood
determined, as the phenotype differed among mice with pressure phenotype, and kidneys of nNOS null mice had
different genetic backgrounds (abstract; Oliverio et al, normal renal histology [53, 54]. However, mice lacking
J Am Soc Nephrol 8:406A, 1997). eNOS are hypertensive and exhibit a small, but signifi-
In contrast to AT-1a2/2 and AT-1b2/2 mice, AT-2 re- cant reduction in heart rate [55]. A possible connection
ceptor deletion resulted paradoxically in increased blood between eNOS and the RAS is indicated by a curious,
pressure and an augmented pressor response to Ang but as yet unexplained observation that plasma renin
activity (PRA) in eNOS2/2 mice is doubled, whereas totalII, suggesting that AT-2 receptors could be involved in
kidney REN mRNA is reduced.mediating depressor effects of Ang II by counteracting
A recent report demonstrated that the hypertensionAT-1a and AT-1b receptor stimulation [47, 48]. How-
in eNOS2/2 mice is most likely a result of abnormal devel-ever, Ang II infusion and AT-2 receptor inhibition in
opmental regulation and remodeling of arterial bloodAT-1a2/2/AT-1b2/2 mice had no effect on blood pressure,
vessels in response to changes in blood dynamics [56].disputing this notion [45]. The observed hypertensive
The carotid arteries of mice lacking eNOS have in-phenotype in AT-22/2 mice could also be influenced by
creased wall thickness and, unlike wild-type mice, de-changes in the CNS, manifested by an impaired drinking
velop medial hyperplasia in response to reduced bloodresponse during water deprivation and an overall reduc-
flow by arterial ligation. In addition, recent studies dem-tion in exploratory behavior.
onstrate that blood vessels from eNOS-deficient miceSome mice have two functional copies of the REN gene,
have an impaired vasodilatory response to acetylcholinewhich, unlike AT-1 receptor, share the same chromo-
[57]. Because similar analysis of kidney arterial vascula-somal locus [28]. Although both Ren-1d and Ren-2d genes
ture has not been performed, the impact of eNOS dele-have each been targeted, a true null mutant cannot be
tion on renal blood vessels remains to be determined.created by simple breeding of Ren-1d2/2 and Ren-2d2/2
mice, and therefore, there is an ongoing effort to develop Bradykinin B2 receptor
a true REN gene null mouse [49, 50]. Nevertheless, the
Kinins, including bradykinin, are known to induce va-
respective REN gene KOs have suggested that although sodilation by activating endothelium-derived relaxing
the two genes are functionally interchangeable, some factor and prostaglandins and play a role in blood pres-
differences regarding differential processing of the two sure homeostasis by regulating the microcirculation of
isoforms exist. Mouse strains lacking Ren-1d or Ren-2d the kidney as well as water and sodium excretion [58, 59].
have normal blood pressure and normal plasma REN Most of the kinin effects are believed to be regulated
activity. The most significant difference between the through one of the two kinin receptors, the B2 receptor.
strains is reverse proportionality in plasma renin concen- Mice lacking bradykinin B2 receptor are normotensive
tration (PRC) and plasma prorenin concentration (PPC). when fed normal salt but develop salt-sensitive hyperten-
The lack of Ren-1d results in overexpression of Ren-2d and sion after prolonged salt loading (3.15% NaCl) [60, 61].
a decrease in the PRC:PPC ratio, whereas the loss of An analysis of renal hemodynamics has shown that, al-
Ren-2d induces Ren-1d gene expression and an increase in though wild-type mice can compensate for the increase
the PRC:PPC ratio. In addition, mice lacking the Ren-1d in blood volume by decreasing renal vascular resistance
gene lack renin-storage granules in juxtaglomerular cells, and increasing renal blood flow, B2 receptor null mice
indicating that Renin-1 secretion is processed primarily have markedly increased renal vascular resistance and
through a regulated (granular) pathway, while Renin-2 a concomitant decrease in renal blood flow.
B2 receptor-deficient mice were also evaluated with re-may be constitutively secreted.
Cvetkovic and Sigmund: Genetic models of hypertension in mice 867
gard to their response to experimental renovascular hyper- blood pressure [68]. ANP has been shown to inhibit
REN and aldosterone secretion and to oppose Ang II-tension simulated by the two-kidney/one-clip method
[62]. Two weeks after clipping the left renal artery, these mediated effects [69]. Mice completely lacking ANP
have slightly increased blood pressure and feature renalmice exhibited a greater increase in arterial pressure and
heart rate, as compared with wild-type and heterozygous defects [70]. They develop hypertension following a two-
week regimen on intermediate-high 2% salt diet, similarmice. This effect seems to be independent of the RAS
because PRA was similarly elevated in both mutant and to heterozygous null mice on a high 8% salt diet [70, 71].
The exact mechanisms underlying salt-sensitive hyper-wild-type mice and AT-1a receptor inhibition had com-
parable effects on blood pressure decrease in all strains. tension are not clear, although the normal reduction in
plasma renin activity in response to salt does not occur
Dopamine receptors in these mice, suggesting irregular regulation of RAS genes
[71]. Targeted ablation of the ANP receptor (GC-A)Dopamine produced in the kidney is an important
regulator of sodium transport, and dysfunction in the also leads to the development of hypertension, although
blood pressure was not further induced by altering di-renal dopaminergic system could be a pathogenetic fac-
tor in genetic hypertension [63]. Dopamine effects in the etary sodium [72]. Another study of ANP receptor A
deficiency reported hypertension, cardiac hypertrophy,kidney are mediated primarily through two dopamine
receptors: D1A receptor, which is located in proximal and sudden death [73].
tubule cells, and D3 receptor, which is located in juxta-
Endothelin-1glomerular cells [63, 64]. Pharmacological inhibition of
dopamine receptor activity has indicated contrasting Endothelin-1 (ET-1) is known as one of the most po-
tent vasoconstrictors and may be involved in the regula-roles of D1A and D3 receptors where D1A receptor stimula-
tion decreases sodium reabsorption and induces REN tion of other genes involved in blood pressure homeostasis
such as renin, ANP, and aldosterone [74, 75]. Thus, it wasrelease and AGT expression, whereas D3 receptor stimu-
lation inhibits REN release. The effect of D1A receptor surprising that a reduction of ET-1 expression in mice
by gene targeting led to an increase in blood pressureloss on blood pressure was evident in heterozygous and
homozygous null mice, both of which developed hyper- rather than a decrease [76]. Although homozygous knock-
out mice develop serious respiratory defects early in devel-tension while maintaining normal serum electrolyte and
calcium ion concentrations [65]. The only measurable opment and die, heterozygous knockouts develop nor-
mally. Their blood pressure is 10 to 15 mm Hg higher thandifference in D1A2/2 mice, apart from increased blood
pressure, was the lack of cAMP production in the kidneys wild-type littermates, while maintaining their response to
ET-1, indicating the absence of gross abnormalities ofin response to dopamine stimulation. The effect on REN,
AGT, and sodium reabsorption was not determined, and the ET-1 signaling pathway. There were no apparent
abnormalities in kidney morphology, and renal functiontherefore, it remains unclear whether the hypertensive
phenotype is due to the abnormal regulation of the RAS. seems to be intact even after prolonged high-salt diet
[77]. It was suggested that this borderline hypertensiveThe inhibiting effect of dopamine on REN production
through D3 receptors was confirmed in D32/2 mice. REN phenotype is primarily due to the loss of the ET-1–
mediated responses in the CNS, which could lead toexpression in these mice was inversely proportional to
the number of copies of the D3 gene [66]. Because renin resetting of the arterial baroreceptor reflex.
Although the effects of the ET-1 deletion were hardactivity is the rate-limiting step in production of Ang II,
even moderate increases in renin concentration observed to explain, the development of mice transgenic for hu-
man ET-1 under endogenous promoter control revealedin heterozygous knockouts led to a 20 mm Hg increase
in blood pressure, the same as in homozygous knockouts. that a modest increase in the concentration of ET-1 in
tissues and plasma was sufficient to cause renal abnor-Upon AT-1a receptor inhibition, systolic blood pressure
of heterozygous and homozygous D3 null mice was nor- malities, including renal cysts and glomerulosclerosis,
and a decrease in glomerular filtration rate [78]. How-malized, further indicating that the hypertensive pheno-
type is a result of abnormal RAS activity. ever, these changes had no effect on blood pressure,
revealing that abnormal expression of the ET-1 gene
Atrial natriuretic peptide and atrial natriuretic seems to be well compensated by other systems regulat-
peptide receptor ing systemic and renal hemodynamics.
Atrial natriuretic peptide (ANP) is secreted into the
Na1/H1 exchangercirculation in response to increased blood pressure, as
detected by atrial distension [67]. It interacts with recep- The role of Na1/H1 exchanger (NHE) on fluid and
electrolyte homeostasis was analyzed in both transgenictors in vasculature, kidney, and adrenal gland, leading
to increased fluid movement from vessels to the extracel- and knockout mouse models. Driven by the sodium gra-
dient produced by Na,K-ATPase, the NHE cotransportslular space, increased salt excretion, and a lowering of
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sodium and hydrogen ions across the basal membrane article is their effects on organ development. Such abnor-
malities in organ function can become a major complicat-of proximal tubule cells regulating sodium reabsorption
in renal tubules and intracellular pH. Mice overexpress- ing factor in establishing the functional relevance of the
manipulated gene. To avoid these problems, new tech-ing rabbit type 1 NHE (NHE1) under control of human
elongation factor 1a promoter exhibit a significant de- niques have been developed that enable scientists to
refine their control over spatial and temporal patternscrease in urinary volume, pH, and sodium, potassium,
and chloride excretion but remain normotensive [79]. of gene expression.
There are several methods that can be used to controlThis phenotype could in part be explained by abnormal
expression of rabbit NHE, as indicated by immunohisto- the tissue- and cell-specificity of transgene expression.
The first general method entails the use of tissue- andchemical evaluation of protein expression in the kidneys
of transgenic mice. The ectopic NHE was detected in cell-specific promoters that carry all elements necessary
and sufficient for the expression of a transgene in a spe-the apical membrane of the medullary collecting tubules
and in epithelial cells of the glomeruli, whereas the en- cific cell type within an organ. Promoters relevant to cell-
specific targeting in kidney are presented in Table 1 anddogenous exchanger is located exclusively at the basolat-
eral membrane of proximal tubules. The overexpression have been reviewed in more detail recently [82]. As
discussed earlier in this article, we have recently shownof rabbit NHE on the apical membrane may lead to
excessive sodium reabsorption through renal tubular the feasibility of this approach in renal research by using
a proximal tubule-specific promoter (KAP) in combina-cells. Although their baseline blood pressure values did
not differ from wild-type mice, they become moderately tion with the hAGT gene, achieving a high level proximal
tubule cell-specific expression of the human transgenehypertensive in response to an intermediate-salt (2%)
or high-salt (8%) diet. The increase in blood pressure in mice [23, 24].
Another way to regulate the spatial expression of awas accompanied by an increase in urinary volume, pH,
and electrolyte excretion to levels similar to those of transgene is by using a gene targeted “knock-in” method.
This is similar to the method used to generate a standardwild-type mice.
knockout mouse except that the targeting vector consistsAdditional analysis of this gene was performed in mice
of a fully functional copy of a transgene placed betweenlacking one of the NHE isoforms. In the mouse, expres-
DNA sequences homologous to the target locus. Thesion of NHE2 and NHE3 overlap in renal proximal tu-
goal of this approach is to insert the transcribed sequencebule cells. Functional deletion of the NHE3 gene allowed
of the transgene of interest into a locus (gene) that hasmore insight into the importance of this gene in blood
a known and favorable spatial and temporal expressionpressure and electrolyte balance homeostasis [80]. Mice
pattern. The result is that the transgene will have a spatiallacking NHE3 have sharply reduced bicarbonate and
and temporal expression profile mimicking that of thefluid reabsorption in both proximal convoluted tubules
substituted endogenous gene. Clearly, although moreand intestines in which NHE3 is also expressed. Although
technically difficult than standard transgenic approaches,compensatory mechanisms are induced in NHE32/2 mice,
it eliminates the copy number and position effects exhib-including an increase in plasma aldosterone and induc-
ited by microinjected transgenes. Moreover, when usingtion of renin mRNA and genes encoding other ion ex-
a cell-specific promoter to target expression in classicchangers, these mice have lowered blood pressure caused
transgenic mice, one must have already dissected theby decreased blood volume. This suggests that NHE3 is
promoter and demonstrated its capability to target ap-a major absorptive NHE in proximal tubule cells and
propriate expression of a heterologous gene in transgenicintestine and that lack of a functional exchanger leads
mice. Because the gene-targeting approach inserts theto impaired acid balance and electrolyte homeostasis in
transgene behind the promoter in its normal location inthe kidney. Disruption of the NHE2 gene causes mainly
the genome, there is essentially no need for an a prioriintestinal abnormalities [81].
assumption as to the location of those elements, except
that they will be linked to the target locus. The only
MOLECULAR GENETIC TOOLS FOR prerequisite for this approach is that the loss of one copy
STUDYING HYPERTENSION IN MICE of the substituted gene will have no adverse effects on
The influence of a genetic manipulation on a specific the development of the system being studied. Chen, Ku-
phenotype can be difficult to predict and interpret if the balak, and Chien recently used this methods to target
genetic change is made in a gene whose product has Cre-recombinase to ventricular myocytes by targeting
numerous functions, such as the RAS. Many of the ef- the endogenous MLC-2v locus [83].
fects of RAS gene manipulation, for example, have been A modification of this approach allows insertion of
manifested by extraordinary effects on kidney develop- gene variants at the hypoxanthine phosphoribosyltrans-
ment. Indeed, one of the major caveats of the transgenic ferase (HPRT) locus [84]. This is achieved in ES cells
harboring an HPRT deletion by using a targeting vectorand systemic knockout models described earlier in this
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Table 1. Promoters for targeting gene expression in the kidney
Promoter Cell specificity References
Kidney androgen-regulated protein (KAP) Proximal tubule [23]
Sodium-hydrogen exchanger (NHE3) Proximal tubule [95]
Plasminogen activator inhibitor (PAI-1) Proximal tubule [96]
Glutamyl transpeptidase (gGT) Proximal tubule [97]
Sodium potassium 2-chloride cotransporter (NKCC2) Thick ascending loop of Henle [98]
Dopamine- and adenosine 39,59-cAMP inhibitor of
protein phosphatase (DARPP-32) Thick ascending loop of Henle [99]
Aquaporin-2 Principal cells of collecting duct [100]
Anion exchanger (AE1) Intercalated cells of collecting duct [101]
Betaine transporter (BGT1) Collecting duct [102]
that reconstitutes HPRT functionality on recombination, is permanent, regardless of the method of delivery, as
the recombination event is essentially irreversible.which then acts as a selectable marker for homologous
recombination. This method produces a transgenic mouse The same system can be used in selective deletion of
a gene in tissues or cell types of interest (Fig. 1) [88].with a single copy of the transgene in a specific and
defined locus in the genome. The main benefit of this The loxP sites can be inserted into intronic regions of a
candidate gene by engineering appropriate vectors andapproach is that it essentially eliminates variability be-
tween individual transgenic mouse lines with regard to subsequent gene targeting in ES cells. The introduced
loxP sites should have no effect on gene expression be-number of integrated copies and their position in the
genome, thus allowing direct comparison of one trans- cause in introns, they would be eliminated during mRNA
processing. The floxed sequence of the modified genegene to another [85]. One can then analyze the effects
of specific gene variants on gene expression in vivo and can be deleted at the DNA level by introducing Cre-
recombinase into specific target tissues using a tissue-their impact on the physiologic system being studied. In
addition, targeting of genes to the HPRT locus can be specific promoter as described previously in this article.
A more detailed explanation of this method has beena useful application for in vivo promoter analysis using
reporter constructs. More recently, specific targeting of described in a recent review, including some of the tech-
nical pitfalls of the approach and possible modificationsa heterologous gene to the apolipoprotein AI-CIII locus
was also described [85]. Comparative expression studies of the system [82, 89].
Genes can also be modified so that their expressionrevealed that the gene was expressed significantly higher
at the apoAI-CIII locus than at the HPRT locus. In addi- can be induced or repressed at will. The two most popular
inducible methods that show promising use in transgeniction, this locus resides on chromosome 9 and thus may
be more advantageous than a locus on the X-chromosome. models are the tetracycline and ecdysone systems (Fig. 3)
[90, 91]. Inducible repression of gene expression can beThe third way of achieving controlled cellular expres-
sion of a transgene is by using the Cre/loxP system (Fig. 1) achieved using the tetracycline system, which relies on
the activity of tetracycline-controlled transactivator pro-[86]. This system uses Cre-recombinase from bacterio-
phage P1, which recognizes two 34 bp sequences, termed tein (tTA) [90, 92]. This is a fusion protein composed
of the bacterial repressor of the tetracycline-resistanceloxP sites. Upon binding to two loxP sites, a Cre tetramer
is formed that induces homologous recombination be- operon fused to the activation domain of the viral protein
VP16. Genes carrying several tandem copies of the tettween the sites, essentially removing the stretch of DNA
sequence flanked by loxP sites. Although the system is operator sequence at their promoter sites are constitu-
tively active in the absence of tetracycline, but are re-widely used to generate tissue-specific knockouts (dis-
cussed later in this article), it can be modified to provide pressed in its presence. Recent modification of this sys-
tem also allows its use as an activator of gene expressionan inducible “on switch” for expression (Fig. 2) [87]. To
accomplish this, the transgene sequence is first modified [93]. A promising new system using the hormone ecdy-
sone from Drosophila melanogaster is being developedso that it contains a “floxed” (region flanked by two loxP
sites) DNA segment containing a “STOP” sequence, for in vivo inducible gene expression [91]. In contrast to
the tetracycline system, ecdysone-regulated gene expres-which prevents gene expression. The transgene can be
activated in mice following elimination of the repressive sion exhibits negligible levels of baseline expression in
the absence of hormone and can be induced several“STOP” element in the presence of Cre-recombinase,
which can be introduced by delivering Cre to specific orders of magnitude, perhaps making it the method of
choice for inducible gene expression. The transcriptionorgans using viral vectors or by mating with mice trans-
genic for a Cre gene driven by a tissue/cell-specific pro- complex for the ecdysone system is a heterodimer con-
sisting of the steroid receptor (EcR) and retinoid recep-moter. The resulting induction of transgene expression
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Fig. 2. Gene induction by Cre/loxP system. (A) Introduction of a floxed
“STOP” DNA element behind the transcription start site inhibits the
expression of the modified gene. The “STOP” element consists of tan-
dem arrays of transcriptional (pA) and translational (UAG) termination
signals which prevent gene expression. (B) In cells expressing Cre-
recombinase, the enzyme recognizes loxP sites and induces homologous
recombination between them. (C) Following the removal of the “STOP”
sequence, expression of the gene is activated. Symbols are: (h) exons;
(m) loxP sites; (gray circles) cre-recombinase.
function in vivo. Researchers can now design and de-
velop strains of mice in which the phenotypes could beFig. 1. Cre/loxP system. Cre/loxP system requires the presence of two
controlled by direct genetic manipulation at any stageloxP sites flanking a DNA segment of interest and expression of Cre-
recombinase. (A) The loxP sites are introduced in vitro into a DNA of their development or in adult animals. Paralleling
segment, which is then targeted to the endogenous locus by homologous the advancements in genetic manipulation methods arerecombination in ES cells. (B) Deletion of the floxed DNA element is
advancements in measurements of physiologic parame-achieved in cells expressing Cre-recombinase. Cre-recombinase assem-
bles at the loxP sites as a dimer (B) and induces recombination between ters in mice, such as renal micropuncture and measure-
loxP sites as a tetramer (C). (D) Upon successful excision of the floxed ments of intra-arterial blood pressure in conscious, freelyDNA sequence, the genomic sequence is irreversibly modified. Symbols
moving mice. Together, they promise to accelerate ourare: (h) exons; (c) loxP sites; (gray circles) cre-recombinase.
understanding of physiological functions under normal
and pathologic conditions for many biological systems.
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two systems, there are new methods being developed APPENDIX
for in vivo induction, such as use of tamoxifen for induc- Abbreviations used in this article are: ACE, angiotensin-converting
tion of embryonic gene expression in utero [94]. enzyme; AGT, angiotensinogen; Ang II, angiotensin II; ANP, atrial
natriuretic peptide; AT-2, angiotensin type 2 receptor; AVP, arginine
vasopressin; CNS, central nervous system; EcR, ecodysone system
steroid receptor; eNOS, endothelial nitric oxide synthase; ES, embry-CONCLUSION
onic stem; ET-1, endothelin-1; hAGT, human angiotensinogen; HPRT,
The combination of the inducible and Cre/loxP sys- hypoxanthine phosphoribosyltransferase; hREN, human renin; iNOS,
inducible nitric oxide synthase; KAP, kidney androgen-inducible pro-tems, with the added ability to selectively manipulate
moter; KO, knockout; NHE, Na1/H1 exchanger; nNOS, neuronal type
the mouse genome by gene targeting in ES cells, has of nitric oxide synthase; PPC, plasma prorenin concentration; PRA,
plasma renin activity; PRC, plasma prorenin concentration; RAS,opened up tremendous opportunities for analyzing gene
Cvetkovic and Sigmund: Genetic models of hypertension in mice 871
Fig. 3. Inducible gene expression. Inducible gene expression is achieved in the presence of a transactivator, whose activity can be modulated by
specific ligands such as tetracycline or ecdysone, and the presence of multiple copies of a corresponding transactivator-responsive cis element in
the promoter of the inducible gene. Transactivator protein remains inactive (open pie shape) in the absence of the ligand and fails to induce
transcription of the gene with the responsive promoter elements (left). The addition of the ligand (pie wedge) influences transactivator activity
through allosteric interaction (completed pie) and induces transcription of the gene (right).
renin-angiotensin system; rAGT, rat angiotensinogen; REN, renin; Yokoyama M, Nomura T, Katsuki M, Nakanishi S: Generation
of transgenic mice with elevated blood pressure by introductionrREN, rat renin; RXR, retinoid receptor; TGF, tubuloglomerular feed-
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